focus -WSS

focus

author：explore 2025-10-01 17:19:03 - browse：51

Blood samples — Marion Berard/AFP/GettyImages

With the advent of disease-modifying Alzheimer’s drugs, everyone in the world of Alzheimer’s diagnostics is bracing for the crush.

Based on their ability to slow cognitive decline, the Eisai/Biogen drug Leqembi won full approval from the FDA this month, and donanemab by Eli Lilly could be approved by year end. Clinicians now have to decide which patients are most suitable for treatment, which means better Alzheimer’s tests need to be developed.

“There’s going to be capacity issues because there’s just not enough neurologists in the world to treat this pool of patients with Alzheimer’s disease at the moment,” said Mark Stearman, a senior international product manager at Roche focusing on Alzheimer’s diagnostics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： FDA panel issues narrow recommendation for Covid vaccine booster doses

focus

WSS

Ventyx halts psoriasis drug development after lackluster trial results

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Methadone doses haven’t kept up in the age of fentanyl

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

American woman, child freed after being kidnapped in Haiti last month

Man killed during FBI raid in connection with threats against Biden, other officials

entertainment

focus

Wikipedia

Tori Bowie and the unacceptable rates of Black maternal death

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Medical leaders decry Supreme Court decision on affirmative action

Wegovy’s successful heart trial raises vital question about weight loss

Drug repurposing or repositioning? The language matters

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Novavax promises a turnaround & Lilly roils the obesity market

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

hotspot

For Cytokinetics, FDA rejection of heart drug would help, not hinder

The best solution to the drug shortages problem

Methadone doses haven’t kept up in the age of fentanyl

FDA reorg will put new emphasis on investigations, sources say

Experimental asthma app from Apple and Anthem shows promise

Maui's cultural, historic landmarks damaged in the devastating wildfires

focus

explore

hotspot

hotspot